Your browser doesn't support javascript.
loading
Association of Low-Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease.
Yen, Chieh-Li; Fan, Pei-Chun; Lee, Cheng-Chia; Chen, Jia-Jin; Kuo, George; Tu, Yi-Ran; Chu, Pao-Hsien; Hsu, Hsiang-Hao; Tian, Ya-Chung; Chang, Chih-Hsiang.
Afiliação
  • Yen CL; Kidney Research Center, Department of Nephrology Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Fan PC; College of Medicine Chang Gung University Taoyuan Taiwan.
  • Lee CC; Kidney Research Center, Department of Nephrology Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Chen JJ; College of Medicine Chang Gung University Taoyuan Taiwan.
  • Kuo G; Kidney Research Center, Department of Nephrology Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Tu YR; College of Medicine Chang Gung University Taoyuan Taiwan.
  • Chu PH; Kidney Research Center, Department of Nephrology Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Hsu HH; College of Medicine Chang Gung University Taoyuan Taiwan.
  • Tian YC; Kidney Research Center, Department of Nephrology Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Chang CH; College of Medicine Chang Gung University Taoyuan Taiwan.
J Am Heart Assoc ; 11(19): e027516, 2022 10 04.
Article em En | MEDLINE | ID: mdl-36172933
Background The benefit of low-density lipoprotein cholesterol (LDL-C) levels in chronic kidney disease populations remains unclear. This study evaluated the cardiovascular and renal outcomes in patients with stage 3 chronic kidney disease with different LDL-C levels during statin treatment. Methods and Results There were 8500 patients newly diagnosed as having stage 3 chronic kidney disease under statin treatment who were identified from the Chang Gung Research Database and divided into 3 groups according to their first LDL-C level after the index date: <70 mg/dL, 70 to 100 mg/dL, and >100 mg/dL. Inverse probability of treatment weighting was performed to balance baseline characteristics. Compared with the LDL-C ≥100 mg/dL group, the 70≤LDL-C<100 mg/dL group exhibited significantly lower risks of major adverse cardiac and cerebrovascular events (6.8% versus 8.8%; subdistribution hazard ratio [SHR], 0.76 [95% CI, 0.64-0.91]), intracerebral hemorrhage (0.23% versus 0.51%; SHR, 0.44 [95% CI, 0.25-0.77]), and new-onset end-stage renal disease requiring chronic dialysis (7.6% versus 9.1%; SHR, 0.82 [95% CI, 0.73-0.91]). By contrast, the LDL-C <70 mg/dL group exhibited a marginally lower risk of major adverse cardiac and cerebrovascular events (7.3% versus 8.8%; SHR, 0.82 [95% CI, 0.65-1.02]) and a significantly lower risk of new-onset end-stage renal disease requiring chronic dialysis (7.1% versus 9.1%; SHR, 0.76 [95% CI, 0.67-0.85]). Conclusions Among patients with stage 3 chronic kidney disease, statin users with 70≤LDL-C<100 mg/dL and with LDL-C <70 mg/dL had similar beneficial effect in the reduction of risks of major adverse cardiac and cerebrovascular events and new-onset end-stage renal disease compared with those with LDL-C >100 mg/dL. Moreover, the 70≤LDL-C<100 mg/dL group seemed to have a lowest risk of intracerebral hemorrhage, although the incidence was low.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal Crônica / Falência Renal Crônica Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Heart Assoc Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal Crônica / Falência Renal Crônica Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Heart Assoc Ano de publicação: 2022 Tipo de documento: Article